| MSF | macrophage slowing factor; macrophage spreading factor; Medicins sans Frontieres [Doctors without Bo... |
|---|---|
| PM | after death (Lat. post mortem); after noon [Lat. post meridiem]; mean pressure; pacemaker; pantomogr... |
| AFP | Alpha(α) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CIDP | Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy |
| AIDP | Acute inflammatory demyelinating polyneuropathy |
|---|---|
| AIF-1 | Allograft Inflammatory Factor-1 |
| CIDP | Chronic Inflammatory Demyelinating Neuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyneuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
|---|---|
| receptors, macrophage colony-stimulating factor | Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response. (12 Dec 1998) |
| chemotactic factors, macrophage | Cytotaxins liberated from normal or invading cells that specifically attract macrophages. They may be lymphokines, products of antigen, antibody and complement interactions or other. (12 Dec 1998) |
| granulocyte-macrophage colony-stimulating factor | <growth factor, haematology, oncology> An acidic glycoprotein of mw 23 kD with internal disulfide bonds. It is produced in response to a number of inflammatory mediators by mesenchymal cells present in the haemopoietic environment and at peripheral sites of inflammation. It stimulates the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from foetal liver progenitor cells. It also has some functional activities in mature granulocytes and macrophages. It is used to promote the recovery of the white blood cells following chemotherapy. Chemical name: Colony-stimulating factor 2 See: colony-stimulating factor. Acronym: GM-CSF (12 Dec 1998) |
| wandering macrophage | <haematology> A macrophage that leaves the blood and migrates to infected tissue. (09 Oct 1997) |
| Hansemann macrophage | Large histiocytes with abundant cytoplasm that may contain Michaelis-Gutmann bodies and one or several nuclei; described in lesions of malacoplakia. (05 Mar 2000) |
| fixed macrophage | A relatively immotile macrophage found in connective tissue, lymph nodes, spleen, and bone marrow. Synonym: resting wandering cell. (05 Mar 2000) |
| free macrophage | An actively motile macrophage typically found in sites of inflammation. (05 Mar 2000) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |